Interleukin IL9 in SPMS
Interleukin IL9 in SPMS
https://jneuroinflammation.biomedcentra ... 20-01770-z
Abstract
Background
Multiple sclerosis (MS) is an immune-mediated, chronic inflammatory, and demyelinating disease of the central nervous system (CNS). Several cytokines are thought to be involved in the regulation of MS pathogenesis. We recently identified interleukin (IL)-9 as a cytokine reducing inflammation and protecting from neurodegeneration in relapsing–remitting MS patients. However, the expression of IL-9 in CNS, and the mechanisms underlying the effect of IL-9 on CNS infiltrating immune cells have never been investigated.
Methods
To address this question, we first analyzed the expression levels of IL-9 in post-mortem cerebrospinal fluid of MS patients and the in situ expression of IL-9 in post-mortem MS brain samples by immunohistochemistry. A complementary investigation focused on identifying which immune cells express IL-9 receptor (IL-9R) by flow cytometry, western blot, and immunohistochemistry. Finally, we explored the effect of IL-9 on IL-9-responsive cells, analyzing the induced signaling pathways and functional properties.
Results
We found that macrophages, microglia, and CD4 T lymphocytes were the cells expressing the highest levels of IL-9 in the MS brain. Of the immune cells circulating in the blood, monocytes/macrophages were the most responsive to IL-9. We validated the expression of IL-9R by macrophages/microglia in post-mortem brain sections of MS patients. IL-9 induced activation of signal transducer and activator of transcription (STAT)1, STAT3, and STAT5 and reduced the expression of activation markers, such as CD45, CD14, CD68, and CD11b in inflammatory macrophages stimulated in vitro with lipopolysaccharide and interferon (IFN)-γ. Similarly, in situ the number of activated CD68+ macrophages was significantly reduced in areas with high levels of IL-9. Moreover, in the same conditions, IL-9 increased the secretion of the anti-inflammatory cytokine, transforming growth factor (TGF)-β.
Conclusions
These results reveal a new cytokine expressed in the CNS, with a role in the context of MS. We have demonstrated that IL-9 and its receptor are both expressed in CNS. Moreover, we found that IL-9 decreases the activation state and promotes the anti-inflammatory properties of human macrophages. This mechanism may contribute to the beneficial effects of IL-9 that are observed in MS, and may be therapeutically potentiated by modulating IL-9 expression in MS.
-
- Similar Topics
- Replies
- Views
- Last post
-
- 3 Replies
- 736 Views
-
Last post by tzootsi
Sat Feb 08, 2020 6:44 am
-
- 0 Replies
- 298 Views
-
Last post by Petr75
Fri Nov 29, 2019 10:27 am
-
- 3 Replies
- 611 Views
-
Last post by frodo
Tue Jan 14, 2020 12:58 am
-
-
Micro-RNA-96 and interleukin-10 biomarkers
by frodo » Fri Jun 21, 2019 10:54 pm » in General Discussion - 0 Replies
- 322 Views
-
Last post by frodo
Fri Jun 21, 2019 10:54 pm
-
-
- 0 Replies
- 424 Views
-
Last post by robbie
Wed Dec 18, 2019 2:47 pm
-
- 7 Replies
- 1357 Views
-
Last post by Jaded
Thu Oct 10, 2019 9:24 am
-
-
PPMS and SPMS may be different
by frodo » Sun Aug 11, 2019 3:53 am » in MS Etiology and Pathogenesis - 0 Replies
- 941 Views
-
Last post by frodo
Sun Aug 11, 2019 3:53 am
-
-
-
Ibudilast for PPMS better than for SPMS
by frodo » Fri Jan 22, 2021 10:52 pm » in MS Etiology and Pathogenesis - 0 Replies
- 253 Views
-
Last post by frodo
Fri Jan 22, 2021 10:52 pm
-
-
-
blood platelets abnormal in SPMS
by frodo » Tue Mar 12, 2019 1:16 am » in Chronic Cerebrospinal Venous Insufficiency (CCSVI) - 0 Replies
- 1002 Views
-
Last post by frodo
Tue Mar 12, 2019 1:16 am
-